1. Introduction: Infection as Cancer Therapy
The idea of using infection to treat cancer is more than a century old. William Coley, in the 1890s, injected bacterial toxins («Coley’s toxins») into inoperable tumors and reported occasional regressions — an observation that anticipated modern immunotherapy. The one bacterial therapy that survived rigorous testing and remains standard of care today is intravesical bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer. BCG is a live attenuated strain of Mycobacterium bovis, long used as a tuberculosis vaccine; instilled into the bladder, it provokes a local immune response that eradicates residual tumor and reduces recurrence. This article reviews BCG’s mechanism, evidence, and the broader field of bacterial cancer therapy.
2. Mechanism of Action
When BCG is instilled into the bladder after transurethral resection, it attaches to the bladder wall (in part via fibronectin) and is internalized by urothelial and immune cells. This triggers a local inflammatory cascade with recruitment of neutrophils, monocytes/macrophages, and lymphocytes and the release of cytokines such as interferons, interleukins, and tumor necrosis factor. The resulting Th1-weighted immune response is thought to be central to its antitumor effect. The precise cellular events linking mycobacterial exposure to tumor cell killing continue to be studied, and the response is not fully understood in mechanistic detail despite decades of use.
3. Technique
BCG is given as an intravesical instillation — a solution placed into the bladder through a catheter and retained for a period, typically repeated weekly during an induction course and then periodically during maintenance. It is used after complete transurethral resection of visible tumor. The schedule and duration of maintenance have been refined by randomized trials.
4. Confirmed Clinical Evidence
4.1. Origin and Randomized Confirmation
The modern use of BCG began with a 1976 report by Morales, Eidinger, and Bruce, which showed reduced recurrence of superficial bladder tumors after intravesical BCG. Multiple randomized trials and meta-analyses subsequently established that BCG reduces recurrence of non-muscle-invasive bladder cancer and, in higher-risk disease, reduces progression. It is generally superior to intravesical chemotherapy agents such as mitomycin C for preventing recurrence, though the relative merits depend on risk group.
4.2. Maintenance Therapy
A Southwest Oncology Group randomized trial led by Lamm and colleagues demonstrated that maintenance BCG improves outcomes compared with induction alone. Maintenance schedules are now standard for the highest-risk non-muscle-invasive disease, including carcinoma in situ.
4.3. Current Position
BCG is the standard adjuvant therapy for high-risk non-muscle-invasive bladder cancer, including carcinoma in situ, and is an option in intermediate-risk disease. It is the only bacterial immunotherapy in routine oncologic use, and its effectiveness is well documented across trials and guidelines.
5. Other Bacterial and Oncolytic Approaches
- Coley’s toxins are historical and not standard; their use declined with the advent of radiotherapy and chemotherapy, and modern trials have not re-established them.
- Oncolytic bacteria (for example, attenuated Salmonella, Clostridium, and Listeria-based agents) are being engineered to colonize tumors and stimulate immunity. These are investigational, with early-phase results and no established standard except BCG.
- Combinations of BCG with checkpoint inhibitors or other immune agents are being studied in BCG-unresponsive disease; some are established alternatives (for example, certain immune-based agents are approved for BCG-unresponsive carcinoma in situ), but the field continues to evolve.
6. Limitations and Toxicity
BCG is a live organism and can cause local and systemic infection. Common effects include cystitis (irritative urinary symptoms), hematuria, and flu-like symptoms; serious complications such as BCG sepsis and disseminated infection are rare but potentially life-threatening and are managed with antituberculous therapy. Absolute contraindications include immunosuppression and active urinary tract infection. A substantial proportion of patients (commonly cited as around 30–40%) do not respond or recur, creating a clinical need for BCG-unresponsive strategies. Global BCG supply shortages have also complicated treatment.
7. Early Research and Emerging Approaches
- Genetically engineered BCG and recombinant mycobacteria aim to enhance immunogenicity; these are early-phase.
- Oncolytic bacteria as delivery vehicles for drugs or immune payloads remain preclinical or in very early trials.
8. Unresolved Questions and Speculative Directions
- The precise immune mechanisms that determine BCG response versus failure are incompletely understood. [Marked for verification.]
- Whether engineered bacteria can be made safe and effective for solid tumors outside the bladder is an open, largely preclinical question.
9. Conclusion
Intravesical BCG is a genuine success of bacterial cancer immunotherapy and the standard adjuvant treatment for high-risk non-muscle-invasive bladder cancer. Its mechanism rests on a local Th1-weighted immune response rather than direct cytotoxicity, and its benefits — reduced recurrence and progression — are confirmed by decades of randomized evidence. Its limitations are toxicity (including rare severe infection), a meaningful failure rate, and supply constraints. Broader bacterial therapies, including Coley’s toxins and engineered oncolytic bacteria, are historical or investigational rather than established treatments.
Sources and Key Research Centers
- National Cancer Institute — bladder cancer treatment including intravesical BCG.
- American Urological Association (AUA) — guidelines on non-muscle-invasive bladder cancer.
- European Association of Urology (EAU) — guidelines on non-muscle-invasive bladder cancer.
- First report of intravesical BCG
- Morales A, Eidinger D, Bruce AW. «Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.» Journal of Urology, 1976; 116(2): 180–183. [Citation details to be verified.]
- Maintenance BCG randomized trial (SWOG)
- Lamm DL, Blumenstein BA, Crissman JD, et al. «Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study.» Journal of Urology, 2000; 163(4): 1124–1129. [Citation details to be verified.]
- ClinicalTrials.gov — trials of BCG combinations and BCG-unresponsive disease (search terms: BCG bladder, BCG unresponsive).
Note: citation identifiers are provided where available; readers should confirm bibliographic details against the publisher’s record. This article is an editorial scientific overview and is not a medical recommendation.